Theratechnologies: Clinical Trials

11 trials sponsored by Theratechnologies, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 3 terminated, 1 active not recruiting. 2 Phase 1, 2 Phase 2, 2 Phase 3, 1 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 12Active not recruiting 1, Completed 1
Phase 22Completed 1, Terminated 1
Phase 32Completed 2
Phase 41Terminated 1

Follow Theratechnologies: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
External Comparison of Ibalizumab in Trials vs. Other Regimens in OPERA
Ibalizumab - HIV-1-infection
CompletedEpividian1412022-08-052023-09-07
The Visceral Adiposity Measurement and Observation Study
Diagnostic Test, HIV Anti-retroviral Background Therapy - HIV, HIV-Infections
CompletedTheratechnologies1962022-04-182023-11-18
A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab
No ibalizumab or Pre-ibalizumab treatment, On ibalizumab treatment - HIV Infections, Multi-Antiviral Resistance
CompletedTheratechnologies1682022-03-222026-07-27
TH1902 in Patients With Advanced Solid Tumors
TH1902 - Solid Tumor, TNBC - Triple-Negative Breast Cancer
Phase 1Active not recruitingTheratechnologies702021-03-042025-04-15
Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®
Tesamorelin for injection - HIV
TerminatedTheratechnologies3912013-02-012018-09-11
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
Tesamorelin, Placebo-Control - Diabetic Retinopathy, HIV
Phase 4TerminatedTheratechnologies1292012-06-012018-09-11
Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting
Tesamorelin, Placebo - Chronic Obstructive Pulmonary Disease (COPD)
Phase 2TerminatedTheratechnologies32011-09-012022-03-18
Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients
Tesamorelin - HIV
Phase 1CompletedTheratechnologies182008-05-012013-12-16
TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy
Tesamorelin, Placebo for Tesamorelin - Lipodystrophy, HIV Infections
Phase 3CompletedTheratechnologies2632007-08-012022-09-30
TH9507 in Patients With HIV-Associated Lipodystrophy
TH9507 - HIV Infections, Lipodystrophy
Phase 3CompletedTheratechnologies4122005-06-012013-11-27
Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes
TH9507 - Type 2 Diabetes
Phase 2CompletedTheratechnologies552002-02-012010-12-21

Conditions studied

HIV Infections (4)  ·  HIV-Associated Lipodystrophy Syndrome (2)  ·  Lipodystrophy (2)  ·  Acquired Immunodeficiency Syndrome (1)  ·  Carcinoma, Ovarian Epithelial (1)  ·  Diabetes Mellitus, Type 2 (1)  ·  Diabetic Retinopathy (1)  ·  Endometrial Neoplasms (1)  ·  Fatty Liver (1)  ·  Liver Cirrhosis (1)  ·  Liver Diseases (1)  ·  Melanoma (1)  ·  Muscular Atrophy (1)  ·  Non-alcoholic Fatty Liver Disease (1)  ·  Prostatic Neoplasms (1)

Interventions

tesamorelin (7)  ·  ibalizumab (2)  ·  Diagnostic Tests, Routine (1)  ·  Hematologic Tests (1)  ·  Injections (1)  ·  Tomography, X-Ray Computed (1)  ·  Urination (1)

Countries

United States (8)  ·  Canada (4)  ·  Belgium (1)  ·  France (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Steven Grinspoon, MD (2)  ·  Funda Meric-Burnstam, MD (1)  ·  Jean-Claude Mamputu, PhD (1)  ·  Jeffery Carr, DR (1)  ·  John Koethe, MD (1)  ·  Jordan Lake, MD (1)  ·  Marilyn De Chantal (1)  ·  Princy N Kumar, MD (1)  ·  Richard Casaburi, PhD, MD (1)  ·  Richard Larouche, MD (1)

Results publications

PMID 20101189, PMID 20554713, PMID 22495074, PMID 28832410, PMID 18057338, PMID 28617838